• Arch Biopartners reported that Royal Columbian Hospital dosed its first patient in a Phase II study of LSALT peptide aimed at preventing acute kidney injury in patients undergoing on-pump cardiac surgery.
• No trial results have been presented; the update focused on enrollment progress as additional sites begin treating patients.
• The study targets lowering the incidence of post-surgery kidney injury, with the broader goal of reducing progression to dialysis or kidney transplant.
• The company is pursuing feasibility discussions to add more trial sites in Canada and the US to support recruitment and expand clinical exposure for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220650PRIMZONEFULLFEED9725200) on May 22, 2026, and is solely responsible for the information contained therein.